Healthy Clinical Trial
— WMMOfficial title:
"When Movement Moves" - A Self-controlled Trial of the Physiological, Mental and Social Health Benefits Among Individuals With Low Physical Mobility Moved by Others in Two Existing Initiatives: the Danish Team Twin and Cycling Without Age
Verified date | April 2023 |
Source | University of Southern Denmark |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of the trial is to investigate the physiological, mental, social health effect among individuals with low physical mobility participating in one of the two pre-existing initiatives: the Danish 'Team Twin' and Cycling Without Age. In these, the individuals with low physical mobility are moved by and together with by normal functioning volunteers. Based on the above, this research project will answer the following research questions: 1. Does movement by others improves the quality of life (QOL) among individuals with low physical mobility 2. Does movement by others improves the physiological health among individuals with low physical mobility 3. Does moving individuals with low physical mobility improve health among normal functioning individuals (i.e volunteer runners and pilots)? 4. How does participation in the physical activity initiatives influence well-being, relations and attitudes among relatives (to the disabled individuals) and employees at nursing homes?
Status | Completed |
Enrollment | 76 |
Est. completion date | February 1, 2022 |
Est. primary completion date | December 1, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Disabled from the departments of TT: - Pass the medical examination conducted by the responsible investigator at the laboratory. Volunteers; - Active member of a local department of TT - Volunteer in Cycling without Age Relatives and nursing home employees; - Relative to the enrolled disabled participant - working at a nursing home who offers CUA Exclusion Criteria: - Sustain damage, which makes the person unable to continue the training sessions. |
Country | Name | City | State |
---|---|---|---|
Denmark | National institute of Public Health | Copenhagen |
Lead Sponsor | Collaborator |
---|---|
University of Southern Denmark | Bevica Fonden, Rigshospitalet, Denmark, Sygekassernes Helsefond |
Denmark,
Jorgensen A, Petersen CB, Eghoj M, Toftager M. When Movement Moves: Study Protocol for a Multi-Method Pre/Post Evaluation Study of Two Programmes; the Danish Team Twin and Cycling Without Age. Int J Environ Res Public Health. 2021 Sep 23;18(19):10008. doi: 10.3390/ijerph181910008. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Quality Of Life (QOL) | Validated self-reported measure of quality of life (i.e. Cantril Ladder) | Baseline to follow-up | |
Secondary | Physiological Health | Measured objectively and by self-report:
Cardiorespiratory and metabolic fitness Cognitive and physical functioning Quantity and severity of symptoms related to their disease/disability Sleep quality and duration |
Baseline to follow-up | |
Secondary | Mental Health | Measured by self-reported questionnaire and interviews:
wellbeing and life satisfaction loneliness Acceptance and coping (learn to live with diagnosis) |
Baseline to follow-up | |
Secondary | Social Health | Measured by interviews and self-reported questionnaire:
Network, relations and Sense of Coherence (SOC) Acceptance from surroundings |
Baseline to follow-up | |
Secondary | Autonomy | Measured by interviews and self-reported questionnaire:
Independence in activities of daily living Feeling of being in control of and taking act in one's own life options and choices |
Baseline to follow-up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |